Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Biostar Pharmaceuticals, Inc. (BSPM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/24/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 07/25/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 07/06/2018 |
8-K
| Other Events |
| 05/30/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 04/23/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 02/02/2018 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits |
| 02/02/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/28/2017 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/18/2017 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/04/2017 |
8-K
| Other Events, Financial Statements and Exhibits |
| 08/28/2017 |
8-K
| Quarterly results |
| 06/12/2017 |
8-K
| Form 8-K - Current report |
| 02/24/2017 |
8-K
| Form 8-K - Current report |
| 02/09/2017 |
8-K
| Form 8-K - Current report |
| 10/12/2016 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 09/22/2016 |
8-K
| Other Events, Financial Statements and Exhibits |
| 06/13/2016 |
8-K
| Form 8-K - Current report |
| 02/24/2016 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"Biostar Pharmaceuticals Regains Compliance with NASDAQ $1.00 Minimum Bid Price XIANYANG, China, February 24, 2016 -- Biostar Pharmaceuticals, Inc. , a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that on February 22, 2016, NASDAQ notified the Company that it had regained compliance with continued listing Rule 5550, which requires a minimum bid price of $1.00 for continued listing on the NASDAQ Stock Market and that the matter was now closed. Ronghua Wang, Biostar’s Chairman and CEO, commenting on the announcement, stated that “Regaining compliance with NASDAQ’s minimum bid price rule is a significant achievement for the Company. With this issue behind us, the Company’s management will continue to pursue its object..." |
|
| 02/05/2016 |
8-K
| Form 8-K - Current report |
| 08/28/2015 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 04/15/2015 |
8-K
| Quarterly results |
| 12/05/2014 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 10/23/2014 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits |
| 03/10/2014 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Placement Agency Agreement, by and away the Company, Moody Capital Solutions, Inc. and Axiom Capital Management, Inc",
"Form of Warrant to purchase Shares of Common Stock by the Company in favor of the Investors",
"Opinion of Schiff Hardin LLP",
"Securities Purchase Agreement, by and between the Company and the Investors",
"Biostar Announces Execution of Agreement for $4.1 Million Registered Direct Offering of Shares of Common Stock and Warrants XIANYANG, China, March 10, 2014 – Biostar Pharmaceuticals, Inc. , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today that it entered into a securities purchase agreement with certain institutional investors for the sale of 1,650,000 shares of common stock in a registered direct offering at the price of $2.49 per share. In addition, warrants to purchase 660,000 shares of common stock in the aggregate will be issued to the investors. The warrants will be exercisable immediately upon issuance at an exercise price of $3.23 per share and expire three years from the date o..." |
|
| 02/20/2014 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 11/27/2013 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 11/13/2013 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"Biostar Pharmaceuticals, Inc. Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule XIANYANG, China, Nov. 13, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on November 11, 2013, NASDAQ notified the Company that it had regained compliance Rule 5550, which requires a minimum bid price of $1.00 for continued listing on the NASDAQ Stock Market and that the matter was now closed. Ronghua Wang, Biostar's Chairman, commenting on the announcement, stated: "We strongly believe that regaining compliance with NASDAQ's continued listing requirements is an important achievement for the Company. Having resolved this issue, we can cont..." |
|
| 11/01/2013 |
8-K
| Form 8-K - Current report |
| 05/06/2013 |
8-K
| Form 8-K - Current report |
| 04/16/2013 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 03/15/2013 |
8-K
| Form 8-K - Current report |
| 01/11/2013 |
8-K
| Form 8-K - Current report |
| 12/20/2012 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/26/2012 |
8-K
| Form 8-K - Current report |
|
|
|